Trials / Unknown
UnknownNCT02532738
The Efficiency of MSC in Refractory Crohn's Disease
A Stage II Clinical Trial Comparing the Efficiacy of Routine Treatment Combined With or Without MSC Therapy in Refractory Crohn's Disease
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 3 (estimated)
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The investigators' preliminary study indicates that MSC is effective therapy in treating IBD. But the standard treatment is still lacking and the effect is not stable in IBD patients. This study is to explore the efficacy and standard strategy when using MSC in refractory IBD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Routine Treatment of CD | The Drug including 6MP, AZA, infliximab and thalidomide |
| BIOLOGICAL | MSC treatment 01 | Injection of 3×10E6/kg of MSC |
| BIOLOGICAL | MSC treatment 02 | Injection of 6×10E6/kg of MSC |
| OTHER | NS | Injection of NS |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2018-11-01
- Completion
- 2018-12-01
- First posted
- 2015-08-26
- Last updated
- 2015-08-26
Source: ClinicalTrials.gov record NCT02532738. Inclusion in this directory is not an endorsement.